These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

104 related articles for article (PubMed ID: 7538710)

  • 21. Clinical comparison of selective and non-selective alpha 1A-adrenoceptor antagonists for bladder outlet obstruction associated with benign prostatic hyperplasia: studies on tamsulosin and terazosin in Chinese patients. The Chinese Tamsulosin Study Group.
    Na YJ; Guo YL; Gu FL
    J Med; 1998; 29(5-6):289-304. PubMed ID: 10503165
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Morning versus evening dosing with doxazosin in benign prostatic hyperplasia: pharmacokinetics, efficacy and safety.
    Kirby RS
    Int J Clin Pract; 1998 Mar; 52(2):75-7. PubMed ID: 9624784
    [No Abstract]   [Full Text] [Related]  

  • 23. [Established and upcoming new options in medical therapy for benign prostatic hyperplasia].
    Schlenker B; Beer AM; Gratzke C; Tilki D; Seitz M; Stief CG; Reich O
    MMW Fortschr Med; 2009 Oct; 151(41):33-6. PubMed ID: 19891182
    [No Abstract]   [Full Text] [Related]  

  • 24. Prostate botulinum A toxin injection--an alternative treatment for benign prostatic obstruction in poor surgical candidates.
    Wein AJ
    J Urol; 2005 Nov; 174(5):1903. PubMed ID: 16217335
    [No Abstract]   [Full Text] [Related]  

  • 25. Symptomatic treatment of benign prostatic obstruction with nicergoline: a placebo controlled clinical study and urodynamic evaluation.
    Ronchi F; Margonato A; Ceccardi R; Rigatti P; Rossini BM
    Urol Res; 1982; 10(3):131-4. PubMed ID: 6182672
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Do alpha1-adrenoceptor antagonists improve lower urinary tract symptoms by reducing bladder outlet resistance?
    Barendrecht MM; Abrams P; Schumacher H; de la Rosette JJ; Michel MC
    Neurourol Urodyn; 2008; 27(3):226-30. PubMed ID: 17638312
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Efficacy and safety of tamsulosin hydrochloride compared to doxazosin in the treatment of Indonesian patients with lower urinary tract symptoms due to benign prostatic hyperplasia.
    Rahardjo D; Soebadi DM; Sugandi S; Birowo P; Djati W; Wahyudi I
    Int J Urol; 2006 Nov; 13(11):1405-9. PubMed ID: 17083392
    [TBL] [Abstract][Full Text] [Related]  

  • 28. An observational urodynamic evaluation of men with lower urinary tract symptoms treated with doxazosin.
    Gerber GS; Kim JH; Contreras BA; Steinberg GD; Rukstalis DB
    Urology; 1996 Jun; 47(6):840-4. PubMed ID: 8677574
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Urodynamic effects of terazosin treatment for Japanese patients with symptomatic benign prostatic hyperplasia.
    Tanaka Y; Masumori N; Itoh N; Sato Y; Takahashi A; Ogura H; Furuya S; Tsukamoto T
    J Urol; 2002 Jun; 167(6):2492-5. PubMed ID: 11992065
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [How effective is beta-sistosterin?].
    Kopper B
    Krankenpfl J; 1999; 37(7-8):285. PubMed ID: 10542556
    [No Abstract]   [Full Text] [Related]  

  • 31. [Combined sabal and urtica extract vs. finasteride in benign prostatic hyperplasia (Alken stages I to II). Comment on the contribution by J. Sokeland and J. Albrech].
    Bartsch G; Dreikom K; Schöntöger PS
    Urologe A; 1998 Jan; 37(1):83-5. PubMed ID: 9540190
    [No Abstract]   [Full Text] [Related]  

  • 32. Bladder outflow obstruction treated with phenoxybenzamine.
    Abrams PH; Shah PJ; Stone R; Choa RG
    Br J Urol; 1982 Oct; 54(5):527-30. PubMed ID: 6184106
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Effect of long-term administration of finasteride (MK-906), an inhibitor of 5 alpha-reductase, in patients with benign prostatic hyperplasia.
    Yoshida O; Oishi K; Okada Y; Mizutani Y; Itokawa Y; Tomoyoshi T; Okada K; Komatz Y; Matsuda T; Takeuchi H
    Hinyokika Kiyo; 1996 Apr; 42(4):323-31. PubMed ID: 8693970
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Risk factors for lower urinary tract symptoms suggestive of benign prostatic hyperplasia in a community based population of healthy aging men: the Krimpen Study.
    Kok ET; Schouten BW; Bohnen AM; Groeneveld FP; Thomas S; Bosch JL
    J Urol; 2009 Feb; 181(2):710-6. PubMed ID: 19091352
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The resolution of detrusor over activity after medical and surgical treatment in patients with bladder outlet obstruction.
    Sriplakich S; Promwatcharanon K
    J Med Assoc Thai; 2007 Nov; 90(11):2326-31. PubMed ID: 18181315
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Prostate botulinum A toxin injection--an alternative treatment for benign prostatic obstruction in poor surgical candidates.
    Kuo HC
    Urology; 2005 Apr; 65(4):670-4. PubMed ID: 15833506
    [TBL] [Abstract][Full Text] [Related]  

  • 37. A double-blind trial of the effect of beta-sitosteryl glucoside (WA184) in the treatment of benign prostatic hyperplasia.
    Kadow C; Abrams PH
    Eur Urol; 1986; 12(3):187-9. PubMed ID: 2423337
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Correlation of the factors on benign prostatic hyperplasia combined with obstruction].
    Chen Q; Wang YX
    Zhonghua Nan Ke Xue; 2002; 8(4):299-301. PubMed ID: 12491701
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [A clinical trial of the treatment of patients with benign prostatic hyperplasia using the alpha 1-adrenoblocker alfuzosin].
    Lopatkin NA; Perepanova TS
    Urol Nefrol (Mosk); 1997; (5):14-6. PubMed ID: 9412005
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Benign prostatic hyperplasia--an old disease picture--from a new viewpoint].
    Hartung R
    Urologe A; 1995 Mar; 34(2):77-83. PubMed ID: 7538713
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.